Jul32019UncategorizedCategory: UncategorizedBy Charlotte Maddalena3 July 2019 Author: Charlotte Maddalena Post navigationPreviousPrevious post:Newsletter June 2019NextNext post:ORPHELIA Pharma and DESITIN GmbH announce the launch of Kigabeq® in GermanyRelated PostsTwo new projects supported by our Endowment Fund21 October 2021Jeremy Bastid and Hugues Bienayme will participate to the SIOPEN annual meeting to be held 6-8 October in Barcelona21 September 2021ORPHELIA Pharma is launching its new corporate website22 July 2021ORPHELIA Pharma and Clinigen sign an exclusive agreement to supply Kigabeq® (vigabatrin)21 July 2021One new project supported by our Foundation Dominique & Tom Alberici24 June 2021ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo®, the first oral liquid formulation of temozolomide16 June 2021
Jeremy Bastid and Hugues Bienayme will participate to the SIOPEN annual meeting to be held 6-8 October in Barcelona21 September 2021
ORPHELIA Pharma and Gustave Roussy announce issuance of European Patent covering Kimozo®, the first oral liquid formulation of temozolomide16 June 2021
